The FLOW Trial: What It Found
The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was the first large-scale outcomes trial to demonstrate that a GLP-1 receptor agonist — specifically semaglutide — provides kidney protection in patients with type 2 diabetes and chronic kidney disease (CKD). The trial was stopped early due to clear efficacy, with semaglutide showing a significant reduction in the composite kidney outcome (kidney failure, sustained 50% reduction in eGFR, and kidney-related death).
For prescribing purposes, this data creates an additional clinical justification for GLP-1 therapy in patients with CKD — independent of the weight management indication. Patients with type 2 diabetes and CKD stages 2-4 now have strong evidence supporting GLP-1 use for kidney protection.
How This Expands Prescribing
The FLOW data has changed prescribing conversations in two ways: prescribers now have stronger clinical justification for starting GLP-1s in CKD patients (who were previously sometimes excluded due to caution), and insurance coverage arguments are stronger because kidney protection represents a high-value clinical outcome that saves insurers significant downstream costs (dialysis, kidney transplant).
If you have CKD and obesity, the overlapping indications — weight management, diabetes management, cardiovascular protection, and now kidney protection — create a comprehensive clinical case for GLP-1 therapy that's difficult for insurers to deny.
Sesame Care
Brand-Name Marketplace
From $99/visit
FDA-approved brand-name medications only (Wegovy, Zepbound, Foundayo). Not compounded.
Paid link Check Eligibility →CKD-Specific Prescribing Considerations
GLP-1 prescribing in CKD patients requires attention to kidney function parameters: eGFR levels, proteinuria, and overall kidney function trajectory. For semaglutide specifically, no dose adjustment is needed for mild-to-moderate CKD (eGFR 30-90). For severe CKD (eGFR 15-30), prescribers may use clinical judgment about benefits versus risks.
The FLOW trial enrolled patients with eGFR 25-75, providing safety and efficacy data across a broad range of kidney function. Your prescriber should be aware of this data when making dosing decisions for your CKD stage.
Building the Insurance Case With Kidney Data
If your prior authorization for a GLP-1 has been denied for the weight management indication, the FLOW kidney protection data provides an additional argument for appeal. Have your prescriber include: your CKD diagnosis and stage, your eGFR trend, your diabetes status, and a reference to the FLOW trial demonstrating kidney-protective benefits. The medical necessity letter should frame GLP-1 therapy as kidney-protective treatment, not solely weight management.
This approach is most effective for patients who have both CKD and type 2 diabetes, as the FLOW trial specifically enrolled this population.
Embody
Top Pick — $400 CPA
From $249/mo
Injectable semaglutide only. Compounded — not FDA-approved.
Paid link Check Eligibility →Wellorithm
Science-Forward
From $199/mo
Compounded — not FDA-approved.
Paid link Check Eligibility →